AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Notably, ropivacaine was found to suppress cell growth and survival in chronic myeloid leukemia by reducing the PI3K/AKT/mTOR pathway [62], and ropivacaine stimulates apoptosis of hepatocellular carcinoma by mediating Akt activity and caspase 3 cleavage [62].